UCB Licenses NextBio Enterprise
CUPERTINO, Calif.–NextBio, developer of an innovative software platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data, today announced a license agreement with global biopharmaceutical company UCB, for NextBio Enterprise. NextBio Enterprise offers life sciences organizations unique tools for knowledge discovery and collaboration, seamless integration of internal and external research data, and secure data access.
“We are very pleased that they are adopting the Enterprise version of the NextBio platform as an integral part of their research and development efforts. UCB’s adoption of NextBio Enterprise will enable its scientists to gain unique insights from data created by diverse high-throughput technologies.”
“UCB is one of the leading biopharmaceutical companies, with operations in Europe, the United States and Asia,” said Saeid Akhtari, co-founder and Chief Executive Officer of NextBio. “We are very pleased that they are adopting the Enterprise version of the NextBio platform as an integral part of their research and development efforts. UCB’s adoption of NextBio Enterprise will enable its scientists to gain unique insights from data created by diverse high-throughput technologies.”
About NextBio
NextBio is the provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data. NextBio’s platform seamlessly combines powerful tools with unique correlated content to transform information into knowledge, providing the foundation for new scientific discoveries. NextBio helps organizations increase productivity and dramatically improve collaboration across therapeutic groups and geographic boundaries. NextBio is delivered as a SaaS (Software as a Service) solution resulting in quick deployment and rapid return on investment.
Today, NextBio is used by researchers at the world’s top commercial and academic institutions. NextBio’s enterprise solution has been deployed at Burnham Institute for Medical Research, Celgene, Eli Lilly, Genzyme, Johnson & Johnson, Merck, Regeneron, Scripps Research Institute, Stanford University, and Takeda, among many others. To learn more about NextBio, please visit our website at https://www.nextbio.com.

